The Vivo X200 features a Dimensity 9400. (Image Source: Vivo)
MediaTek’s Dimensity 9500 flagship chipset will just about beat Qualcomm’s Snapdragon 8 Elite 2 to launch. Like the Qualcomm chipset, the Dimensity 9500 has now appeared on Geekbench aboard the Vivo X300, revealing some of its more important details.
Recent reports indicate MediaTek plans on taking the wraps off its next-gen flagship chipset, the Dimensity 9500, next month. The SoC will be adopted by a slew of Chinese OEMs and has now appeared on Geekbench aboard the Vivo X300.
The chipset visited the popular benchmark platform on a device bearing the model number “V20509A”. That phone is said to be the Vivo X300, which can be expected to debut in China before the end of the year as a direct rival to the Xiaomi 15’s (buy on Amazon) successor.
Unfortunately, the Dimensity 9500 fails to show off its performance chops in this listing. It manages scores of just 2,485 and 7,321 on the single-code and multi-core tests respectively. That’s performance on par with 2023’s Dimensity 9300, indicating that the test was carried out with the chipset in some sort of shackled form.
The listing itself reveals some key bits of information on the Dimensity 9500. The chipset will maintain the octa-core setup of its predecessor, but with four cores running at 2.70 GHz, three cores at 3.50 GHz, and a prime core at 4.21 GHz. It’s unknown exactly what cores those will be, but prior information points at new Cortex A7-series cores and a new Cortex X9-series core from ARM. On the GPU end, the listing also confirms the presence of ARM’s new Mali-G1-Ultra MC12 as previously reported.
Ricci Rox – Senior Tech Writer – 3039 articles published on Notebookcheck since 2017
I like tech, simple as. Half the time, you can catch me writing snarky sales copy. The rest of the time, I’m either keeping readers abreast with the latest happenings in the mobile tech world or watching football. I worked as both a journo and freelance content writer for a couple of years before joining the Notebookcheck team in 2017. Feel free to shoot me some questions on Twitter or Reddit if it so tickles thine fancy.
“Weapons” creeped back to the top of box office charts, collecting a significant $25 million in its second weekend of release. Ticket sales for the R-rated horror film declined just 43% from its $43 million debut, an impressive hold for a genre that’s known to drastically fall after opening weekend.
En route to sleeper hit status, “Weapons” has grossed $89 million domestically and $148 million worldwide after two weekends of release. The film, which cost a modest $38 million, is benefitting from great reviews and electric word-of-mouth. It’s the fifth consecutive hit for Warner Bros. following “A Minecraft Movie,” “Sinners,” “Final Destination Bloodlines” and “Superman.” Fortunes have reversed for the studio after starting the year with such financial misfires as “Mickey 17” and “The Alto Knights.”
This weekend’s only major new release, Universal’s action thriller “Nobody 2,” didn’t pack too strong a punch. The film, starring Bob Odenkirk as a seemingly mild-mannered dad who actually kicks ass and takes names, landed at No. 3 with $9.2 million from 3,260 North American theaters. That’s just barely ahead of its predecessor, 2021’s “Nobody,” which debuted to $6.8 million domestically while cinemas were just starting to reopen and playing to limited capacity after COVID. Overseas the movie added $4.9 million for a global tally of $14.1 million.
Timo Tjahjanto took over directing duties from the original’s filmmaker Ilya Naishuller. In the follow-up, Odenkirk’s character Hutch Mansell takes his family on vacation to the small tourist town of Plummerville and finds himself in the crosshairs of several shady locals. Audience scores for the sequel weren’t as positive as the first; “Nobody 2” earned a “B+” grade on CinemaScore compared to the original’s “A-” grade. “Nobody 2” was modestly priced at $25 million, just above the first film’s $16 million price tag.
“‘Nobody 1’ cost very little to make for a studio action picture and was comfortably profitable,” says analyst David A. Gross of Franchise Entertainment Research. “‘Nobody 2’ is an opportunity to earn a few more dollars without a lot of risk. At [its] price, the picture should make money.”
In second place, Disney’s “Freakier Friday” also enjoyed a solid second weekend with $14.5 million from 3,975 venues, a 50% decline from its opening. The PG sequel, reuniting Lindsay Lohan and Jamie Lee Curtis as mother and daughter who swap places, has earned $54.6 million in North America and $86.3 million worldwide after 10 days of release.
Another Disney film, the Marvel superhero adventure “The Fantastic Four: First Steps,” plunged to the No. 4 spot with $8.8 million in its fourth weekend of release. After a promising $117 million bow, “Fantastic Four” has been quickly losing steam at the box office with ticket sales at $247 million in North America and $468.7 million worldwide after four weekends. Those returns are above this year’s prior Marvel entries, February’s “Captain America: Brave New World” ($415 million globally) and May’s “Thunderbolts” ($382 million globally). But after a rocky post-pandemic stretch, this performance doesn’t yet signal a return to box office glory for the Marvel Cinematic Universe.
“The Bad Guys 2” rounded out the top five with $6.9 million in its third outing. Universal and DreamWorks Animation’s heist comedy has generated $56 million domestically and $117 million globally. By comparison, the first “Bad Guys” was a slow-and-steady hit with $250 million over the course of its entire run.
In sixth place, “Superman” added $5.3 million in its sixth weekend in theaters. The comic book adaptation from Warner Bros. and DC has grossed $340 million in North America and $594 worldwide to date. In a matter of days, it’ll become one of six films this year to cross the $600 million mark.
Elsewhere, Sydney Sweeney’s crime thriller “Americana” cratered with $500,000 from 1,110 locations for a dismal start in 16th place. It’s one of the worst openings in history for a film that landed on more than 1,000 screens. Co-starring Paul Walter Hauser, Halsey and Eric Dane, the Western follows a gaggle of characters on the trail of a rare Native American artifact. Lionsgate acquired the film at SXSW in 2023 and pre-sold international rights, which helps to recoup losses for underperforming theatrical releases.
“The film was made in 2022 and finished in 2023, so it’s been sitting for over two years,” says Gross. “Time to get it out, move it through its release windows, and put it on TV to generate some income.”
The overall box office is 6.4% ahead of last year — a margin that has been shrinking over the past few weeks. In early July, for example, revenues were 16% ahead of 2024. And returns for the four-month stretch that comprises the summer season are stalling at $3.4 billion through mid-August. That likely means the movie theater industry’s goal of hitting the elusive $4 billion mark — a once-common milestone that has only been achieved one time since the pandemic — won’t be within reach.
“Alas, it’s not in the cards at this point,” says senior Comscore analyst Paul Dergarabedian of the $4 billion mark. “That said, it’s been an amazing summer movie season.”
BUNER: Pakistani rescuers dug homes out from under massive boulders on Sunday as they searched for survivors of flash floods that killed at least 344 people, with more than 150 still missing.
Since Thursday, torrential rains across the country have caused flooding, rising waters and landslides that have swept away entire villages and left many residents trapped in the rubble.
Most of the deaths, 317, were reported in Khyber Pakhtunkhwa province, where monsoon rains that are only expected to intensify in the days ahead drove flooding and landslides that collapsed houses.
More than 150 people are missing in hardest-hit Buner district, where at least 208 people were killed and “10 to 12 entire villages” were partially buried, officials told AFP.
“They could be trapped under the rubble of their homes or swept away by floodwaters,” said Asfandyar Khattak, head of Khyber Pakhtunkhwa’s Provincial Disaster Management Authority.
“Separately, in Shangla district, dozens of people are also reported missing,” Khattak added.
“There is no electricity or mobile signal in Buner, as power lines and mobile towers were damaged,” he added.
Local residents sit beside the damaged homes following Friday’s flash flooding at a neighborhood of Pir Baba, an area of Buner district, in Pakistan’s northwest on Aug 17, 2025. (AP)
The spokesman for the province’s rescue agency told AFP that around 2,000 rescue workers were involved across nine districts, where rain was still hampering efforts.
“The operation to rescue people trapped under debris is ongoing,” said Bilal Ahmad Faizi.
“The chances of those buried under the debris surviving are very slim,” he added.
AFP journalists in Buner saw half-buried vehicles and belongings lying strewn in the sludge, with mud covering houses and shops.
A grave digger, Qaiser Ali Shah, told AFP he dug 29 burial places in the last two days.
“I have also dug six graves for children. With each grave, it felt as though I was digging it for my own child,” he told AFP.
“For the first time, my body simply refused to carry me through. That’s why today I apologized and said I cannot do this work anymore.”
Flooded roads hampered the movement of rescue vehicles, as a few villagers worked to cut fallen trees to clear the way after the water receded.
“Our belongings are scattered, ruined and are in bad shape,” shopkeeper Noor Muhammad told AFP as he used a shovel to remove mud.
“The shops have been destroyed along with everything else. Even the little money people had has been washed away,” he added.
The provincial government has declared the severely affected mountainous districts of Buner, Bajaur, Swat, Shangla, Mansehra and Battagram as disaster-hit areas.
“We were trapped in our homes and could not get out,” another Buner resident, Syed Wahab Bacha, told AFP.
“Our entire poor community has been affected… This road was our only path, and it too has been washed away,” he added.
On Saturday, hundreds gathered for mass funerals, where bodies wrapped in blood-stained white shawls were laid out on the village ground.
Fallen trees and straw debris were scattered across nearby fields, while residents shovelled mud out of their homes.
Pakistan’s meteorological department has forecast “torrential rains” with monsoon activity “likely to intensify” from Sunday onwards.
The monsoon season brings South Asia about three-quarters of its annual rainfall, vital for agriculture and food security, but also brings destruction.
“The intensity of this year’s monsoon is around 50 to 60 percent more than last year,” said Lt. Gen. Inam Haider, chairman of the national disaster agency.
“Two to three more monsoon spells are expected until the first weeks of September,” he told journalists in Islamabad.
Landslides and flash floods are common during the season, which usually begins in June and eases by the end of September.
The torrential rains that have pounded Pakistan since the start of the summer monsoon have killed more than 650 people, with more than 920 injured.
Pakistan is one of the world’s most vulnerable countries to the effects of climate change and is contending with extreme weather events with increasing frequency.
Monsoon floods in 2022 submerged a third of the country and killed around 1,700 people.
Another villager in Buner told AFP on Saturday that residents had spent the night searching through the rubble of their former homes.
“The entire area is reeling from profound trauma,” said 32-year-old schoolteacher Saifullah Khan.
“I helped retrieve the bodies of the children I taught. I keep wondering what kind of trial nature has imposed on these kids,” he said.
US Secretary of State Marco Rubio attends an event at the US Department of State in Washington, DC, US, July 16, 2025. — Reuters
US Secretary of State Marco Rubio on Sunday warned of “consequences,” including the potential imposition of new sanctions on Russia, if no peace deal is reached on Ukraine, ahead of a key meeting at the White House.
“If we’re not going to be able to reach an agreement here at any point, then there are going to be consequences,” he told US broadcaster NBC.
“Not only the consequences of the war continuing but the consequences of all those sanctions continuing and potentially new sanctions on top of it as well.”
The United States will keep trying to create a scenario to help end Russia’s war in Ukraine, but that might not be possible, US Secretary of State Marco Rubio told CBS on Sunday.
“If peace is not going to be possible here and this is just going to continue on as a war, people will continue to die by the thousands … we may unfortunately wind up there, but we don’t want to wind up there,” Rubio said in an interview with “Face the Nation.”
European leaders will accompany Ukrainian President Volodymyr Zelenskiy to meet Donald Trump in Washington on Monday, seeking to bolster him as the US president presses Ukraine to accept a quick peace deal after Trump’s meeting with Russian leader Vladimir Putin on Friday.
“There are things that were discussed as part of this meeting that are potentials for breakthroughs, that are potential for progress,” said Rubio, adding that topics for discussion would include security guarantees for Ukraine.
According to sources, Trump and Putin discussed proposals for Russia to relinquish tiny pockets of occupied Ukraine in exchange for Ukraine ceding a swathe of fortified land in the east and freezing the front lines elsewhere.
Rubio said both sides would need to make concessions if a peace deal were to be concluded.
Terence Stamp, the English actor who played the arch-villain General Zod in Superman films, has died at the age of 87.
In a career that spanned six decades, the Oscar-nominated actor starred in films including The Adventures of Priscilla, Queen of the Desert, Far From the Madding Crowd and Valkyrie.
Stamp died on Sunday morning, his family said in a statement to Reuters news agency.
“He leaves behind an extraordinary body of work, both as an actor and a writer that will continue to touch people for years to come,” they said.
Born in Stepney, east London, to working-class parents on 22 July 1938, Stamp attended grammar school before pursuing a career in advertising.
After securing a scholarship to go to drama school, he shot to fame in the 1960s, making his debut playing the titular role in Billy Budd, a 1962 film about a naive young seaman in the 18th century.
His performance earnt him an Oscar nomination for best supporting actor and a Golden Globe for best newcomer.
He went on to make a name for himself as a villain, with stand-out performances in Superman and Superman II as General Zod,kidnapperFreddie Clegg in The Collector, and Sergeant Troy in Far From the Madding Crowd.
During his heyday in the 1960s, Stamp was known for his good looks, fashion sense and high-profile girlfriends, including actress Julie Christie – who he later starred alongside in Far From the Madding Crowd – and supermodel Jean Shrimpton.
His relationship with Christie only lasted a year but was immortalised by the Kinks in the song Waterloo Sunset with the line “Terry meets Julie”, believed to reference the pair.
Stamp was approached to replace Sean Connery when he relinquished his role as James Bond, but said his radical ideas about how he could interpret the character put off producer Harry Saltzman.
“I think my ideas about it put the frighteners on Harry,” he said. “I didn’t get a second call from him.”
He spent some time in Italy, working with directors Pier Paolo Pasolini and Federico Fellini, but found his star had faded when he returned to London at the end of the 1960s.
“When the 1960s ended, I think because I’d been so identified with it, I kind of ended as well,” he later told BBC Radio 4’s Desert Island Discs.
“I thought if I could be good looking, and I could be successful and I could be famous, everything would be solved. And when it all kind of came to an end, I thought to myself there’s been a lot of fun but there hasn’t been any real, deep internal satisfaction.”
He moved away from acting for a while, buying a round-the-world ticket and ending up in India where he studied yoga and spent time living in a spiritual retreat – before being offered his most high-profile role, as General Zod in Superman, in 1976.
Returning to the silver screen, the following decades saw dozens of appearances in films including Star Wars: Episode I – The Phantom Menace, A Song for Marion, The Adjustment Bureau and Last Night in Soho.
One of his most celebrated and notable performances came in 1994 when he played a transgender woman in the Australian film, The Adventures of Priscilla, Queen of the Desert.
Stamp was reportedly onboard to return for a sequel to Priscilla, director Stephan Elliott confirmed last year.
Elliott described the then 85-year-old Stamp as the “fittest man I’ve ever met in my life” who “has never drunk and basically eats grass”.
“It took him a long time to think about it until he got there,” he told The Guardian, “but eventually he said to me, ‘You know what? You’re right. We’re not finished yet. The story is untold.’”
Neoadjuvant immunotherapy combined with chemotherapy has demonstrated promising efficacy and an acceptable safety profile in patients with limited-stage small cell lung cancer (LS-SCLC), according to a recent meta-analysis. The findings suggest this approach could offer a new therapeutic strategy for a disease with a historically poor prognosis, particularly for patients with more advanced disease.
The meta-analysis, which pooled data from 6 studies and 114 patients, found that neoadjuvant chemoimmunotherapy led to high rates of pathological complete response (pCR) and major pathological response (MPR), key indicators of treatment effectiveness before surgery. It also confirmed that most patients undergoing this treatment were able to achieve a successful R0 surgical resection, meaning no visible or microscopic tumor was left behind.
“The current research findings demonstrate that neoadjuvant immunotherapy has shown promising clinical efficacy and acceptable safety in SCLC,” the study’s authors concluded. “These results provide valuable reference for upcoming clinical trials regarding the optimal neoadjuvant strategy and potential beneficiary populations.”
Addressing an Unmet Need in SCLC
SCLC, which accounts for 10% to 15% of all lung cancers, is notoriously aggressive, with rapid progression and a high risk of metastasis. Despite improvements in treatment, the 5-year survival rate remains under 7%. While immunotherapy has revolutionized care for extensive-stage SCLC, its role in the limited-stage setting has been less defined.
The National Comprehensive Cancer Network (NCCN) guidelines recommend surgery for early-stage (I-IIA) SCLC, with chemoradiotherapy being the standard of care for later-stage (IIB-IIIC) disease. However, outcomes remain suboptimal for locally advanced cases, highlighting a critical need for new treatment strategies. Neoadjuvant therapy, which aims to shrink tumors before surgery, has shown success in other cancer types and is now being explored as a way to improve surgical outcomes and long-term survival in SCLC.
Key Findings from the Analysis
Researchers conducted a systematic review and meta-analysis of studies published through February 10, 2025. They specifically looked at pathological response rates and safety outcomes, including R0 resection rates and treatment-related severe adverse events (tr-SAEs). All included studies were from China, which the authors noted as a limitation on the generalizability of the results. However, they pointed out that ongoing trials in other regions are expected to provide more diverse data in the future.
The pooled analysis of six studies found a pCR rate of 35% (95% CI 14%-56%) and an MPR rate of 49% (95% CI 18%-80%). In terms of safety, the pooled R0 surgical resection rate was 95% (95% CI 88%-100%), and the incidence of tr-SAEs was 44% (95% CI 13%-76%). Notably, no perioperative deaths were reported across any of the studies.
A subgroup analysis suggested a potential correlation between the number of neoadjuvant treatment cycles and pathological response. Patients who received more than 2 cycles of therapy appeared to have a higher rate of both pCR (45% vs 10%) and MPR (63% vs 0%) compared to those who received only 2 cycles. While this finding is based on a small number of studies, it points to a critical area for future research.
“With the increasing number of neoadjuvant treatment cycles, the incidence of preoperative adverse reactions may increase,” the authors wrote. “Nonetheless, most patients achieved R0 resection, with a low incidence of postoperative AEs and no perioperative mortality, indicating that the optimal neoadjuvant treatment regimen in SCLC patients remains worthy of exploration.”
The analysis also found a high objective response rate (ORR) of 91% based on RECIST 1.1 criteria, with no significant differences observed across different study types or neoadjuvant therapy cycles.
Implications for Clinical Practice and Future Research
The data from this meta-analysis supports the ongoing exploration of neoadjuvant chemoimmunotherapy as a viable option for patients with LS-SCLC. With 81% of the patients included in the analysis having stage III disease, the results are particularly relevant for this patient population, which has limited treatment options outside of chemoradiotherapy.
The findings highlight the need for further research to determine the optimal number of neoadjuvant therapy cycles, identify the best candidates for this treatment approach, and evaluate long-term survival outcomes. Several ongoing clinical trials are investigating neoadjuvant immunotherapy in SCLC, with trial NCT04539977 and ChiCTR2100042367 being two examples.
REFERENCE:
Ge F, Lin G, Huo Z, et al. A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer. Thorac Cancer. 2025 Aug 11;16(15):e70125. doi: 10.1111/1759-7714.70125
The cast of Severance, Apple TV+’s acclaimed psychological drama, reunited this weekend as production questions continue to loom over season three.
Adam Scott, Britt Lower, Tramell Tillman, Zach Cherry, John Turturro, and Patricia Arquette appeared together on the red carpet at the Television Academy’s inaugural Televerse Festival, held Saturday (August 16) at JW Marriott LA Live in Los Angeles. Series director Ben Stiller and creator Dan Erickson also joined the event, sparking excitement among fans eager for any hint of progress on the show’s future.
Despite the high-profile reunion, Apple TV+ executives have confirmed that filming for season three has not yet begun. Head of programming Matt Cherniss told Variety last month that while development is moving forward, a production start date has not been set. The series previously faced a three-year gap between its first two seasons.
“No one wants another three-year wait,” Cherniss explained. “I don’t believe we have a start date yet, but we’re moving in that direction.”
Adam Scott also recently revealed on Amy Poehler’s “Good Hang” podcast that filming season two took nearly 186 days, highlighting the demanding production schedule. Some episodes stretched to six weeks of shooting, as the show films multiple installments simultaneously.
While fans celebrated the reunion, speculation remains about which cast members will return and how long the wait for new episodes will be. With its growing acclaim and intense fan interest, Severance season three is one of Apple TV+’s most anticipated projects.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from the week (Monday, August 11, to Friday, August 15, 2025), and click on each link to read and watch anything you may have missed.
A JAMA Network Open research letter analyzing passive smartphone activity data from over 11,000 students found that adolescents with smartphones at school spent nearly an hour per day using them, with most of that time on social media. Data from the Aura parental monitoring app, collected between September 2024 and February 2025, showed that 71% of monitored weekdays included school-hour phone use. Students aged 14–17 used smartphones more than younger peers, averaging 55.9 minutes on social media compared to 42.4 minutes for those aged 10–13.
Click here for the full article.
A study in JAMA Pediatrics found that a tidal volume of at least 4 mL/kg may be an optimal target for achieving successful lung aeration in preterm neonates during delivery room resuscitation. Researchers analyzed data from more than 240 infants born between 22 and 31 weeks’ gestation who required positive pressure ventilation (PPV). Effective lung aeration was defined as a sustained heart rate of at least 100 beats per minute within the first 10 minutes after birth. Of all respiratory parameters measured, only expiratory tidal volume (VTE) was significantly associated with this outcome.
Click here for the full article.
CDC data from the 2024 National Immunization Survey-Teen showed year-over-year increases in adolescent vaccination rates, with Tdap coverage rising to 91.3% and MenACWY to 90.1% among teens aged 13 to 17 years. Smaller gains were also seen for MMR, hepatitis B, and meningococcal B vaccines, while HPV vaccination rates held steady at about 78% for at least one dose. Coverage for Tdap and MenACWY exceeded 90% in most states, reflecting ongoing public health efforts, though disparities persisted—particularly lower HPV vaccination recommendations in rural areas compared with urban ones. Click here for the full article.
The FDA has approved Viatris’ iron sucrose injection, USP, as the first generic version of Venofer for treating iron deficiency anemia (IDA) in adults and children aged 2 years and older with chronic kidney disease (CKD). Available in multiple single-dose vial strengths, the intravenous therapy also received competitive generic therapy designation for certain doses, granting expedited review and potential market exclusivity.
Click here for full approval details.
On August 12, 2025, the FDA approved brensocatib (BRINSUPRI; Insmed) as the first treatment for non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older. The oral DPP1 inhibitor targets neutrophilic inflammation, aiming to reduce pulmonary exacerbations—a hallmark of NCFB. Approval was based on phase 3 ASPEN trial results, where both 10 mg and 25 mg doses significantly reduced annual exacerbation rates, prolonged time to first exacerbation, and increased the proportion of patients who remained exacerbation-free over 52 weeks compared with placebo.
NCFB affects an estimated 500,000 people in the U.S. and millions worldwide, causing chronic airway widening, mucus buildup, and recurrent infections. Experts say the approval marks a major advance in care, offering the first FDA-approved therapy to address the disease’s underlying inflammatory pathway.
MUNICH (Germany) – Lauri Markkanen once again proved he’s Europe’s hottest hand, dropping 42 points to lead Finland past Poland 97-88, securing their third consecutive victory in their FIBA EuroBasket 2025 preparation campaign.
The Utah Jazz star was nearly flawless, shooting 10-of-17 from the field and an outstanding 19-of-20 from the free-throw line, while also collecting 12 rebounds in just 24 minutes of action.
Related Articles
Who will be the next EuroBasket scoring champion?
Earlier this summer, Markkanen shattered the Finnish national team’s scoring record with a 48-point outburst against Belgium, then followed it up with a smooth 31-point performance in the rematch.
Through three games, the forward is averaging 40.3 points per contest, putting him on pace to challenge some of the highest marks in EuroBasket history. Greece legend Nikos Galis still holds the competition record with 37.0 points per game, set in 1987.
Date
Opposition
Result
Points
August 8
Belgium
105-62
48
August 11
Belgium
92-74
31
August 17
Poland
97-88
42
Finland, co-hosts of FIBA EuroBasket 2025, will face Germany, Lithuania, Montenegro, Great Britain, and Sweden in Group B action in Tampere.
Chelsea’s latest crop of summer signings failed to find a way past an organised Crystal Palace side as the London rivals played out a season-opening goalless draw at Stamford Bridge on Sunday.
Eberechi Eze thought he had scored for Palace in the first half with a well-hit free kick in the first half but the video assistant referee (VAR) and referee Darren England ruled that Marc Guéhi was too close to the Chelsea wall and it was ruled out.
Neither side came close to scoring from there as two well-drilled defences cancelled each other out.
– Follow ESPN’s live coverage of all the big moments from Sunday
